Scott Bizily Sells 1,750 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,750 shares of the stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $25.74, for a total transaction of $45,045.00. Following the transaction, the insider now directly owns 1,737 shares in the company, valued at approximately $44,710.38. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Monday, April 1st, Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.78, for a total transaction of $259,102.34.
• On Wednesday, March 27th, Scott Bizily sold 5,833 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $35.04, for a total transaction of $204,388.32.
• On Monday, March 18th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $31.27, for a total transaction of $54,722.50.
• On Tuesday, February 27th, Scott Bizily sold 1,909 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $57,270.00.
• On Friday, February 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $27.67, for a total transaction of $48,422.50.
• On Thursday, February 8th, Scott Bizily sold 6,244 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $27.50, for a total transaction of $171,710.00.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT opened at $25.25 on Friday. 4D Molecular Therapeutics, Inc. has a 1 year low of $9.44 and a 1 year high of $36.25. The stock has a market cap of $1.29 billion, a P/E ratio of -9.49 and a beta of 2.87. The firm has a 50-day moving average of $28.90 and a 200 day moving average of $20.22.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.09). 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 34.14%. The business had revenue of ($0.02) million for the quarter, compared to analysts’ expectations of $4.67 million. Research analysts expect that 4D Molecular Therapeutics, Inc. will post -3.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its holdings in 4D Molecular Therapeutics by 16.7% in the third quarter. Bank of New York Mellon Corp now owns 135,711 shares of the company’s stock worth $1,728,000 after buying an additional 19,434 shares during the last quarter. Trexquant Investment LP purchased a new position in 4D Molecular Therapeutics in the third quarter worth about $566,000. Aigen Investment Management LP purchased a new position in 4D Molecular Therapeutics in the third quarter worth about $216,000. Wellington Management Group LLP raised its holdings in 4D Molecular Therapeutics by 2.2% in the third quarter. Wellington Management Group LLP now owns 172,722 shares of the company’s stock worth $2,199,000 after buying an additional 3,638 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of 4D Molecular Therapeutics by 359.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company’s stock valued at $100,000 after purchasing an additional 3,873 shares during the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group reissued a “buy” rating and issued a $81.00 price target on shares of 4D Molecular Therapeutics in a report on Wednesday, February 7th. Royal Bank of Canada lifted their target price on shares of 4D Molecular Therapeutics from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. BMO Capital Markets cut their target price on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday, April 1st. Jefferies Financial Group lifted their target price on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, March 1st. Ten research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $44.22.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.